Experience with Leuprorelin Acetate as a Depot Formulation for Prostate Cancer in a Long-Term Follow-Up Study
- 12 Downloads
Carcinoma of the prostate is a significant cause of morbidity and mortality in men aged 60 years and over. With the increasing life expectancy and improved screening, the incidence and prevalence of prostatic carcinoma have increased, particularly in developed countries. The incidence of newly diagnosed cases is the highest in the USA (75 per 100 000) and ranges from 10 to 40 per 100 000 in Europe . In 1975, prostatic carcinoma was the second most common male cancer in industrialised countries and the third most frequent cause of death from cancer in men, accounting for about 10% of such deaths . While the true prevalence of prostatic carcinoma is unknown, it has been estimated to range from 5% to 40% of men over 50 years and in a series of autopsies has been as high as 67% of men over 80 years old . Even though the great majority of cases are not diagnosed, prostatic carcinoma must be the most prevalent carcinoma in men. The effective management of such a dominant carcinoma can only become increasingly important in the future.
Unable to display preview. Download preview PDF.
- 2.Di Silvero F (1975) Histological type of tumor and hormone dependence. In: Bracci U, Di Silvero (eds) Hormonal therapy in prostate cancer. Cofese Edizioni, Palermo, pp 47–58Google Scholar
- 5.Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer II. The effects of castration on advanced carcinoma of prostatic gland. Arch Surg 43: 209–223Google Scholar
- 8.Newling DWW, Dennis L, Mahler C, Debruyne FMJ, Lunglmayr G, Robinson MRG, Richards B (1987) Clinical and endocrinological results with a biodegradeable depot LHRH analogue (Zoladex) in the management of advanced prostatic cancer. In: Chisholm GD (ed) Zoladex: a new treatment for prostatic cancer. Society of Medicine London, pp 17–24 (International Congress and Symposium Series number 125 )Google Scholar
- 13.Veterans Administrative Collaborative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017Google Scholar
- 14.Waterhouse J, Shanmugaratham K, Muir C, Powell J (1982) Cancer incidence in five continents, vol IV. IARC, Lyon (IARC Scientific Publications no. 42 )Google Scholar
- 15.World Health Organization (1979)Google Scholar